15 semaglutide FDA approves obesity drug that

Download the whitepaper here: #GLP1 #ConsumerHealth #Nutrition #ObesityManagement #VitafoodsEurope

Start your journey toward a healthier, happier you with expert tips and insights.

Today our partner Amylyx Pharmaceuticals shared exciting news: the nomination of AMX0318 as a development candidate - a novel, long-acting GLP-1 receptor antagonist identified through our collaboration

Originally developed for diabetes management, these therapies have demonstrated significant effectiveness in weight management and are reshaping conversations around obesity treatment, chronic disease prevention, and long-term healthcare costs

Are you considering Semaglutide injections for your weight loss journey